Our pipeline

We have an exciting and balanced pipeline underpinned by great science.

Latest quarterly updates

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.


183

projects in our pipeline

16

new molecular entities in our late-stage pipeline

2

new molecular entities under review



Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).

Filter By:

Oncology (as of 29 April 2022)

Phase I

Phase I

  • AZD0466 haematological malignancies
  • AZD1390 glioblastoma
  • AZD2936 solid tumours
  • AZD5991 haematological malignancies
  • AZD7648 solid tumours
  • AZD7789 solid tumours, haematological malignancies
  • AZD8205 solid tumours
  • AZD8701 +/- Imfinzi solid tumours
  • Imfinzi + adavosertib solid tumours
  • IPH5201 solid tumours
  • MEDI1191 solid tumours
  • MEDI5752 + Lenvatinib advanced renal cell carcinoma
  • MEDI9253 solid tumours
  • Tagrisso + (Koselugo or savolitinib) TATTON advanced EGFRm non-small cell lung cancer

Phase II

Phase II

  • adavosertib ovarian cancer, solid tumours, uterine serous cancer
  • AZD0171 + Imfinzi + CTx 1st-line metastatic pancreatic ductal adenocarcinoma
  • AZD4573 haematological malignancies
  • AZD4573 + Calquence haematological malignancies
  • AZD5305 solid tumours
  • camizestrant oestrogen receptor +ve breast cancer
  • capivasertib prostate cancer
  • ceralasertib solid tumours
  • Imfinzi (platform) COAST non-small cell lung cancer
  • Imfinzi (platform) HUDSON post IO non-small cell lung cancer
  • Imfinzi (platform) NeoCOAST non-small cell lung cancer
  • Imfinzi + Lynparza ORION 1st-line metastatic non-small cell lung cancer
  • Imfinzi + monalizumab solid tumours
  • MEDI5752 solid tumours
  • oleclumab+CTx or Imfinzi+oleclumab+CTx metastatic pancreatic cancer
  • Tagrisso + savolitinib SAVANNAH advanced EGFRm non-small cell lung cancer

Phase III

Phase III

  • camizestrant + CDK4/6i SERENA-6 1st-line HR+ HER2- ESR1m breast cancer
  • camizestrant + palbociclib SERENA-4 1st-line HR+ HER2- breast cancer
  • capivasertib + abiraterone CAPItello-281 PTEN deficient metastatic hormone sensitive prostate cancer
  • capivasertib + CTx CAPItello-290 1st-line metastatic triple negative breast cancer
  • capivasertib + fulvestrant + palbociclib CAPItello-292 1st-line triplet in early relapse/ET resistant locally advanced (inoperable) or metastatic breast cancer
  • capivasertib + fulvestrant CAPItello-291 2nd-line and beyond in AI resistant locally advanced (inoperable) or metastatic breast cancer
  • datopotamab deruxtecan TROPION-Breast01 2-3L HR+ HER2- breast cancer
  • datopotamab deruxtecan TROPION-Lung01 2L+ NSCLC without actionable genomic mutations
  • Imfinzi + treme + TACE +/- Lenvatinib EMERALD-3 locoregional hepatocellular carcinoma
  • Imfinzi + tremelimumab + SoC NILE 1st-line urothelial cancer
  • Imfinzi + tremelimumab HIMALAYA 1st-line hepatocellular carcinoma
  • Imfinzi +/- tremelimumab + CRT ADRIATIC 1st-line limited-stage small-cell lung cancer
  • Imfinzi +/- tremelimumab + CTx POSEIDON 1st-line non-small cell lung cancer
  • Lynparza + Imfinzi + bevacizumab DUO-O 1st-line ovarian cancer
  • Lynparza + Imfinzi DUO-E 1st-line endometrial cancer
  • monalizumab + cetuximab INTERLINK-1 2L+ relapsed metastatic head and neck squamous cell cancer
  • savolitinib + Imfinzi SAMETA 1st-line papillary renal cell carcinoma

LCM Projects

LCM Projects

  • Calquence + R-CHOP ESCALADE 1st-line diffuse large B cell lymphoma
  • Calquence + venetoclax + obinutuzumab AMPLIFY 1st-line chronic lymphocytic leukaemia
  • Calquence ASCEND relapsed/refractory chronic lymphocytic leukaemia
  • Calquence ECHO 1st-line mantle cell lymphoma
  • Calquence ELEVATE-TN 1st-line chronic lymphocytic leukaemia
  • Enhertu (platform) DESTINY-Breast07 HER2+ breast cancer
  • Enhertu (platform) DESTINY-Breast08 HER2-low breast cancer
  • Enhertu DESTINY-Breast02 HER2-positive, unresectable and/or metastatic breast cancer pretreated with prior standard of care HER2 therapies, including T-DM1
  • Enhertu DESTINY-Breast03 HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane
  • Enhertu DESTINY-Breast04 HER2-low, unresectable and/or metastatic breast cancer subjects
  • Enhertu DESTINY-Breast05 HER2-positive post-neoadjuvant high-risk breast cancer
  • Enhertu DESTINY-Breast06 post-ET HER2-low/HR+ breast cancer 2L
  • Enhertu DESTINY-Breast09 1st-line HER2-positive breast cancer
  • Enhertu DESTINY-Breast11 Neoadjuvant HER2-positive breast cancer
  • Enhertu DESTINY-Gastric01 HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens
  • Enhertu DESTINY-Gastric04 2nd-line HER2-positive gastric
  • Enhertu DESTINY-Lung01 HER2-over-expressing or -mutated, unresectable and/or metastatic non-small cell lung cancer
  • Enhertu DESTINY-Lung04 1st-line HER2m non-small cell lung cancer
  • Enhertu DESTINY-PanTumour01 HER2 mutant tumours
  • Enhertu DESTINY-PanTumour02 HER2-expressing solid tumours
  • Imfinzi PEARL 1st-line metastatic non-small cell lung cancer
  • Imfinzi (platform) BEGONIA 1st-line metastatic triple negative breast cancer
  • Imfinzi (platform) MAGELLAN 1st-line metastatic non-small cell lung cancer
  • Imfinzi + CRT KUNLUN locally advanced oesophageal squamous cell carcinoma
  • Imfinzi + CRT PACIFIC-2 locally-advanced (stage III) non-small cell lung cancer
  • Imfinzi + CRT PACIFIC-5 (China) locally-advanced (stage III) non-small cell lung cancer
  • Imfinzi + CTx MERMAID-1 stage II-III adjuvant non-small cell lung cancer
  • Imfinzi + CTx neoadjuvant AEGEAN locally-advanced (stage II-III) non-small cell lung cancer
  • Imfinzi + CTx NIAGARA muscle invasive bladder cancer
  • Imfinzi + CTx TOPAZ-1 1st-line biliary tract cancer
  • Imfinzi + domvanalimab (AB154) + CTx PACIFIC-8 unresectable stage III non-small cell lung cancer
  • Imfinzi + EV +/- treme VOLGA muscle invasive bladder cancer
  • Imfinzi + FLOT MATTERHORN Neo-adjuvant/adjuvant gastric cancer
  • Imfinzi + VEGF + TACE EMERALD-1 locoregional hepatocellular carcinoma
  • Imfinzi + VEGF EMERALD-2 adjuvant hepatocellular carcinoma
  • Imfinzi +- oleclumab +- mona unresectable stage III NSCLC PACIFIC-9 NSCLC
  • Imfinzi MERMAID-2 stage II-III premetastatic non-small cell lung cancer
  • Imfinzi post-SBRT PACIFIC-4 stage I/II non-small cell lung cancer
  • Imfinzi POTOMAC non muscle invasive bladder cancer
  • Lynparza (basket) MK-7339-002 / LYNK002 HRRm cancer
  • Lynparza + abiraterone PROpel prostate cancer
  • Lynparza LYNK-003 platinum sensitive 1st-line colorectal cancer
  • Lynparza MONO-OLA1 1st-line BRCAwt ovarian cancer
  • Lynparza OlympiA gBRCA adjuvant breast cancer
  • Tagrisso + CTx FLAURA2 1st-line advanced EGFRm non-small cell lung cancer
  • Tagrisso +/- CTx neoadjuvant NeoADAURA stage II/III resectable EGFRm NSCLC
  • Tagrisso ADAURA adjuvant EGFRm non-small cell lung cancer
  • Tagrisso LAURA stage III EGFRm non-small cell lung cancer
  • Tagrisso ORCHARD platform study 2nd-line EGFRm osimertinib-resistant NSCLC

Cardiovascular, Renal and Metabolism (as of 29 April 2022)

Phase I

Phase I

  • AZD2373 nephropathy
  • AZD2693 non-alcoholic steatohepatitis
  • AZD3366 cardiovascular disease
  • AZD3427 cardiovascular disease
  • AZD5462 cardiovascular disease
  • AZD7503 non-alcoholic steatohepatitis
  • MEDI8367 chronic kidney disease

Phase II

Phase II

  • AZD4831 heart failure with a preserved ejection fraction
  • AZD5718 coronary artery disease / chronic kidney disease
  • AZD8233 hypercholesterolemia
  • AZD8601 cardiovascular disease
  • AZD9977 + Farxiga/Forxiga heart failure with CKD
  • cotadutide type-2 diabetes, obesity and NASH, diabetic kidney disease
  • MEDI6570 cardiovascular disease
  • tozorakimab diabetic kidney disease
  • zibotentan + Farxiga/Forxiga ZENITH-CKD chronic kidney disease

Phase III

Phase III

  • eplontersen patients with hereditary or wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR CM)
  • eplontersen patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN)
  • roxadustat OLYMPUS ROCKIES anaemia in chronic kidney disease/end-stage renal disease

LCM Projects

LCM Projects

  • Andexxa (ALXN2070) Acute Major Bleed
  • Andexxa (ALXN2070) urgent surgery
  • Brilinta/Brilique THALES acute ischaemic stroke or transient ischaemic attack
  • Bydureon BCise (autoinjector) type-2 diabetes
  • Farxiga/Forxiga DAPA-CKD renal outcomes and cardiovascular mortality in patients with chronic kidney disease
  • Farxiga/Forxiga DAPA-MI Prevention of heart failure and CV death following a myocardial infarction
  • Farxiga/Forxiga DELIVER worsening HF or CV death in patients with chronic heart failure (HFpEF)
  • Lokelma DIALIZE-Outcomes CV outcomes in patients on chronic haemodialysis with hyperkalaemia
  • Lokelma STABILIZE-CKD hyperkalaemia in CKD
  • roxadustat anaemia in myelodysplastic syndrome
  • roxadustat chemotherapy induced anaemia
  • Xigduo XR/Xigduo type-2 diabetes

Respiratory & Immunology (as of 29 April 2022)

Phase I

Phase I

  • AZD4604 asthma
  • AZD5055 idiopathic pulmonary fibrosis
  • AZD8630 asthma

Phase II

Phase II

  • AZD1402 asthma
  • AZD7986 chronic obstructive pulmonary disease
  • brazikumab EXPEDITION ulcerative colitis
  • navafenterol chronic obstructive pulmonary disease
  • tozorakimab Asthma
  • tozorakimab COVID-19
  • tozorakimab Atopic Dermatitis

Phase III

Phase III

  • brazikumab INTREPID Crohn's disease
  • Fasenra CALIMA SIROCCO ZONDA BISE BORA GREGALE MIRACLE severe uncontrolled asthma
  • PT027 asthma
  • Saphnelo TULIP 1 & TULIP 2 AZALEA (China) systemic lupus erythematosus
  • Tezspire NAVIGATOR DIRECTION severe uncontrolled asthma
  • tozorakimab COPD

LCM Projects

LCM Projects

  • Breztri/Trixeo (PT010) KALOS LOGOS asthma
  • Fasenra ARROYO chronic spontaneous urticaria
  • Fasenra FJORD bullous pemphigoid
  • Fasenra HILLIER atopic dermatitis
  • Fasenra HUDSON eosinophilic gastritis and eosinophilic gastroenteritis
  • Fasenra MAHALE non-cystic fibrosis bronchiectasis
  • Fasenra MANDARA eosinophilic granulomatosis with polyangiitis
  • Fasenra MESSINA eosinophilic esophagitis
  • Fasenra NATRON hypereosinophilic syndrome
  • Fasenra ORCHID nasal polyps
  • Fasenra RESOLUTE chronic obstructive pulmonary disease
  • Saphnelo lupus nephritis
  • Saphnelo TULIP-SC systemic lupus erythematosus (subcutaneous)
  • Tezspire COURSE chronic obstructive pulmonary disease
  • Tezspire WAYPOINT nasal polyps

Rare Disease (as of 29 April 2022)

Phase I

Phase I

  • ALXN1720 generalised myasthenia gravis
  • ALXN1820 haematology
  • ALXN1850 hypophosphatasia
  • NI006 transthyretin amyloid cardiomyopathy

Phase II

Phase II

  • ALXN2050 paroxysmal nocturnal haemoglobinuria
  • danicopan (ALXN2040) geographic atrophy

Phase III

Phase III

  • acoramidis (ALXN2060) transthyretin amyloid cardiomyopathy
  • ALXN1840 Wilsons disease
  • CAEL-101 AL amyloidosis
  • danicopan (ALXN2040) paroxysmal nocturnal haemoglobinuria with extravascular haemolysis
  • Koselugo/selumetinib SPRINT paediatric neurofibromatosis type-1

LCM Projects

LCM Projects

  • Ultomiris (ALXN1210) complement-mediated thrombotic microangiopathy
  • Ultomiris (ALXN1210) dermatomyositis
  • Ultomiris (ALXN1210) generalised myasthenia gravis
  • Ultomiris (ALXN1210) haematopoietic stem cell transplant–associated thrombotic microangiopathy
  • Ultomiris (ALXN1210) neuromyelitis optica spectrum disorder
  • Ultomiris (ALXN1210) subcutaneous, paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome

Vaccine & Immune therapies (as of 29 April 2022)

Phase I

Phase I

Phase II

Phase II

Phase III

Phase III

  • Evusheld prevention and treatment of COVID-19
  • nirsevimab passive RSV immunisation
  • Vaxzevria COVID vaccine

LCM Projects

LCM Projects

Other (as of 29 April 2022)

Phase I

Phase I

  • AZD4041 opioid use disorder
  • MEDI0618 osteoarthritis pain
  • MEDI1341 parkinson's disease
  • MEDI1814 alzheimer’s disease

Phase II

Phase II

  • MEDI7352 osteoarthritis pain and painful diabetic neuropathy

Phase III

Phase III

LCM Projects

LCM Projects

Removed since last quarter